These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20022911)

  • 1. Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models.
    Vermaat JS; van der Tweel I; Mehra N; Sleijfer S; Haanen JB; Roodhart JM; Engwegen JY; Korse CM; Langenberg MH; Kruit W; Groenewegen G; Giles RH; Schellens JH; Beijnen JH; Voest EE
    Ann Oncol; 2010 Jul; 21(7):1472-1481. PubMed ID: 20022911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients.
    Vermaat JS; Gerritse FL; van der Veldt AA; Roessingh WM; Niers TM; Oosting SF; Sleijfer S; Roodhart JM; Beijnen JH; Schellens JH; Gietema JA; Boven E; Richel DJ; Haanen JB; Voest EE
    Eur Urol; 2012 Oct; 62(4):685-95. PubMed ID: 22285764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
    Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
    Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy.
    Tamura K; Ando R; Takahara K; Ito T; Kanao K; Yasui T; Shiroki R; Miyake H
    Urol Oncol; 2021 Jan; 39(1):78.e1-78.e8. PubMed ID: 32958444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer.
    Wood SL; Rogers M; Cairns DA; Paul A; Thompson D; Vasudev NS; Selby PJ; Banks RE
    Br J Cancer; 2010 Jun; 103(1):101-11. PubMed ID: 20531413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
    Mathieu R; Pignot G; Ingles A; Crepel M; Bigot P; Bernhard JC; Joly F; Guy L; Ravaud A; Azzouzi AR; Gravis G; Chevreau C; Zini L; Lang H; Pfister C; Lechevallier E; Fais PO; Berger J; Vayleux B; Roupret M; Audenet F; Descazeaud A; Rigaud J; Machiels JP; Staehler M; Salomon L; Ferriere JM; Kleinclauss F; Bensalah K; Patard JJ
    Urol Oncol; 2015 Aug; 33(8):339.e9-15. PubMed ID: 26087971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
    Findeisen P; Zapatka M; Peccerella T; Matzk H; Neumaier M; Schadendorf D; Ugurel S
    J Clin Oncol; 2009 May; 27(13):2199-208. PubMed ID: 19307507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma.
    Yamamoto Y; Matsuyama H; Matsumoto H; Sakano S; Fuji N; Oba K; Yamamoto M; Kamiryo Y; Hiragino T; Nagao K; Takai K; Aoki A
    Jpn J Clin Oncol; 2020 Feb; 50(2):214-220. PubMed ID: 31755525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma.
    Stenman M; Laurell A; Lindskog M
    Med Oncol; 2014 Mar; 31(3):841. PubMed ID: 24477648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients.
    Tolson J; Bogumil R; Brunst E; Beck H; Elsner R; Humeny A; Kratzin H; Deeg M; Kuczyk M; Mueller GA; Mueller CA; Flad T
    Lab Invest; 2004 Jul; 84(7):845-56. PubMed ID: 15107802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial Sloan-Kettering Cancer Center intermediate risk features by modern strategy including molecular-targeted therapy in clinical practice.
    Kamba T; Yamasaki T; Teramukai S; Shibasaki N; Arakaki R; Sakamoto H; Matsui Y; Okubo K; Yoshimura K; Ogawa O
    Int J Clin Oncol; 2014; 19(3):505-15. PubMed ID: 23813043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study.
    Kubackova K; Melichar B; Bortlicek Z; Pavlik T; Poprach A; Svoboda M; Lakomy R; Vyzula R; Kiss I; Dusek L; Prausova J; Buchler T;
    Target Oncol; 2015 Dec; 10(4):557-63. PubMed ID: 25903462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma.
    Giridhar KV; Sosa CP; Hillman DW; Sanhueza C; Dalpiaz CL; Costello BA; Quevedo FJ; Pitot HC; Dronca RS; Ertz D; Cheville JC; Donkena KV; Kohli M
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29099775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib.
    Kwon WA; Cho IC; Yu A; Nam BH; Joung JY; Seo HK; Lee KH; Chung J
    Ann Surg Oncol; 2013 Dec; 20(13):4397-404. PubMed ID: 24081805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
    Iacovelli R; Lanoy E; Albiges L; Escudier B
    BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline Edmonton Symptom Assessment System and survival in metastatic renal cell carcinoma.
    Graham J; Gingerich J; Lambert P; Alamri A; Czaykowski P
    Curr Oncol; 2018 Aug; 25(4):e319-e323. PubMed ID: 30111978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment Lymphocyte to Monocyte Ratio is an Independent Prognostic Factor in Metastatic Clear Cell Renal Cell Carcinoma.
    Gu L; Ma X; Xie Y; Li H; Wang L; Chen L; Zhao W; Zhang Y; Zhang X
    Clin Genitourin Cancer; 2017 Jun; 15(3):e369-e377. PubMed ID: 28038932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma: Model development and external validation with Memorial Sloan Kettering Cancer Center model and the international metastatic renal cell carcinoma database consortium model.
    Shin D; Jeong CW; Song C; Kang M; Seo SI; Kim JK; Lee H; Chung J; Hong SH; Hwang EC; Kwak C; Park JY
    Medicine (Baltimore); 2021 Aug; 100(31):e26826. PubMed ID: 34397846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression and clinical significance of serum protein among patients with clear-cell renal cell carcinoma.
    Nuerrula Y; Rexiati M; Liu Q; Wang YJ
    Cancer Biomark; 2015; 15(4):485-91. PubMed ID: 26406868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline tumor volume in assessing prognosis of patients with intermediate-risk synchronous metastatic renal cell carcinoma.
    de Bruijn RE; Nijkamp J; Noe A; Horenblas S; Haanen JB; Prevoo W; Bex A
    Urol Oncol; 2016 Jun; 34(6):258.e7-258.e13. PubMed ID: 26822077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.